TLN-05220, TLN-05223, new Echinosporamicin-type antibiotics, and proposed revision of the structure of bravomicins

Journal of Antibiotics

Volumn 62, Issue 10, 2009, Pages 565-570

  Banskota, Arjun H ^a   Aouidate, Mustapha ^b   Sørensen, Dan ^c   Ibrahim, Ashraf ^b   Piraee, Mahmood ^d   Zazopoulos, Emmanuel ^b   Alarco, Anne Marie ^b   Gourdeau, Henriette ^b   Mellon, Christophe ^b   Farnet, Chris M ^b   Falardeau, Pierre ^b   McAlpine, James B ^b  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b Thallion Pharmaceuticals Inc   (Canada)

^c MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^d BIOTICA TECHNOLOGY LTD   (United Kingdom)

Author keywords

Antibacterial; Anticancer; Bravomicin; Micromonospora echinospora; Polycyclic aromatic; TLN 05220; TLN 05223

Indexed keywords

2 PYRIDONE DERIVATIVE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BRAVOMICIN A; CYCLOPHOSPHAMIDE; ECHINOSPORAMICIN; PYRAN; SIMAOMICIN ALPHA; TLN 05220; TLN 05223; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL STRAIN; CANCER GROWTH; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; MALE; MASS SPECTROMETRY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE TUMOR; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR CELL LINE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA; CELL LINE, TUMOR; ENTEROCOCCUS; GRAM-POSITIVE BACTERIA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, NUDE; MICROBIAL SENSITIVITY TESTS; MICROMONOSPORA; MOLECULAR SEQUENCE DATA; POLYCYCLIC HYDROCARBONS, AROMATIC; PROSTATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; VANCOMYCIN RESISTANCE;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROMONOSPORA ECHINOSPORA; POSIBACTERIA;

EID: 70449097485     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2009.77     Document Type: Article

References (16)

1. Alarco, A. M., Banskota, A., McAlpine, J., Farnet, C., Falardeau, P. & Zazopoulos, E. Profiling of new antitumor natural products discovered using a genomics/cheminformatics- based drug discovery platform. Proc. Am. Assoc. Cancer Res. 47, A1992 (2006).
2. Gross, H. Genome mining-a concept for the discovery of new natural products. Curr. Opin. Drug Discov. Devel. 12, 207-219 (2009).
3. Zazopoulos, E. et al. A genomics-guided approach for discovering and expressing cryptic metabolic pathways. Nat. Biotechnol. 21, 187-190 (2003).
4. Zazopoulos, E. & Farnet, C. M. Improving drug discovery from microorganisms. Natural Products: Drug Discovery and Therapeutic Medicine (eds Zhang, L. and Demain, A. L.) 95-106 (Humana Press Inc., Totowa, NJ, USA, 2005).
5. McAlpine, J. B. et al. Microbial genomics as a guide to drug discovery and structural elucidation: ECO-02301, a novel antifungal agent, as an example. J. Nat. Prod. 68, 493-496 (2005).
6. Banskota, A. H. et al. Isolation and identification of three new 5-Alkenyl-3,3(2H)- furanones from two Streptomyces species using a genomic screening approach. J. Antibiot. 59, 168-176 (2006).
7. Waitz, J. A., Marquez, J. A., Patel, M. G. & Horan, A. C. Broad spectrum antibiotic complex produced by a novel micromonospora. US 4,440,751, April 3 (2001).
8. Srensen, D., McAlpine, J. B., Piraee, M., Farnet, C. M. & Zazopoulos, E. Genome scanning technology reveals an antibacterial compound (ECO-0501) of a new structural class from the vancomycin-producer Amycolatopsis orientalis 44th ICAAC: no. F-720a, Washington, DC (2004).
9. McAlpine, J. B. et al. The power of genomic analysis in the discovery of novel secondary metabolites 46th Annual Meeting of American Society of Pharmacognosy: no., Corvallis, OR, USA (2005).
10. Gurevich, A. I. et al. The structure of albofungin. Tet. Lett. 13, 1751-1754 (1972).
11. Carter, G. T., Goodman, J. J., Torrey, M. J., Borders, D. B. & Gould, S. J. Biosynthetic origin of the carbon skeleton of sisaomicin A, a hexacyclic xanthone antibiotic. J. Org. Chem. 54, 4321-4323 (1989).
12. He, H., Yang, H. Y., Luckman, S. W. & Bernam, V. S. Antibiotic P175-A and semisynthetic derivatives thereof US Patent Application. US 2004/0220195 Nov. 4, (2004).
13. He, H. et al. Echinosporamicin, a new antibiotic produced by Micromonospora echinospora ssp. echinospora, LL-P175. Helv Chim. Acta 87, 1385-1391 (2004).
14. Shu, Y-Z., Chen, J., Lam, K. S., Veitch, J. A. & Brown, D. Antibiotic Bravomicins US Patent 5, 994, 543, Nov. 30, (1999).
15. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Fifth Edition (NCCLS document M7-A5, ISBN 1-56238-394-399 Pennsylvania, USA).
16. Plumb, J. A., Milroy, R. & Kaye, S. B. Effects of the pH dependence of 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res. 49, 4435-4440 (1989).